MedTrace Logo

Safety Study of Immune System Modulator for Autoimmune Diseases

NCT02243683 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2015-10-14

No results posted yet for this study

Summary

The purpose of this study is to determine the toxicity, tolerability and safety of single ascending doses of AX-024.HCl in healthy male subjects.

Conditions

  • Healthy Volunteers

Interventions

DRUG

AX-024.HCl

OTHER

Placebo

Sponsors & Collaborators

  • Simbec Research

    collaborator INDUSTRY

  • ORION Clinical Services

    collaborator INDUSTRY

  • Packaging Coordinators Inc

    collaborator OTHER

  • Centro de Biología Molecular Severo Ochoa, Spain (CBMSO)

    collaborator UNKNOWN

  • Artax Biopharma Inc

    lead INDUSTRY

Principal Investigators

  • Girish Sharma, MBBS · Simbec Research

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2014-11-30
Completion
2015-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02243683 on ClinicalTrials.gov